JPMorgan Reinstates Teva Pharma (TEVA) at Overweight
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $13.18 +0.69%
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 19
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 19
Join SI Premium – FREE
JPMorgan reinstated coverage on Teva Pharma (NYSE: TEVA) with an Overweight rating and a price target of $82.00 (prior $70.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $69.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Maxim Group Starts Amazon.com (AMZN) at Buy
- Jones Trading Starts Rezolute (RZLT) at Buy, 'an under-appreciated player in the rare disease space'
- Sage Therapeutics (SAGE) PT Lowered to $17 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT Change, New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
